On May 7, we held the NJ Chapter Meeting of GISTers at the LRG Office in Wayne, NJ. It was a great gathering of patients, caregivers, LRG staff members and our guest speaker ,Dr. Bob Maki of Mt. Sinai Hospital in New York.
"Acceptance – for me that means trying to live as positively and naturally as possible by thinking of cancer as a friend and not as an enemy!"
Approximately 90 GIST patients, relatives, GIST experts, interested professionals, physicians and representatives of the pharmaceutical industry gathered in Zurich on April 8, 2011 for the eighth meeting of the Swiss GIST group in the Restaurant Au Premier at Zurich Main Station (HB Zürich).
Where does GIST come from? Good question. GIST actually begins formation in special cells called interstitial cells of Cajal (ICCs). ICCs are considered the pace-makers of the GI tract...
Here is a video from the Life Raft Group called GIST 2010: A Decade of Difference! See how far we have come in just ten years in the treatment and research of [...]
Scott Gottlieb has fired a shot across the FDA's statisticalconfidence bow. The former FDA Deputy Commissioner, using the Wall Street Journal as his command post, charges the regulator with "steadily disregarding" the provisions of the FDA Modernization Act that give it "broad discretion" to reduce the quantity and rigor of clinical data needed to approve drugs targeting grave illnesses.
Italian GISTers hold 4th national meeting Written by Gabriella Tedone A .I.G.’s (Associazione Italiana GIST) fourth national meeting was held at Fondazione IRCCS Istituto Nazionale dei Tumori (INT) in Milan on February 26, 2011. The focus [...]
Go inside the Fletcher Science Lab at Brigham & Women's with David Josephy and Dr. Jonathan Fletcher. David Josephy is the President of Life Raft Group Canada, a member of the LRG Science Team, and [...]
“I learned a lot and feel so much better having the NIH team as an additional resource, “said LRG member, Anne Pacifico.
Food and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual one-on-one dialogue with leaders of approximately 60 patient organizations at a forum hosted by the National Organization for Rare Disorders (NORD).
